Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity

BJU International

Volumn 105, Issue 9, 2010, Pages 1268-1275

  Nitti, Victor W ^a   Rovner, Eric S ^c   Bavendam, Tamara ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Detrusor overactivity; Overactive bladder; Urinary incontinence

Indexed keywords

FESOTERODINE; PLACEBO;

ABDOMINAL PAIN; ABNORMAL VISION; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; DYSURIA; EPISTAXIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEMATURIA; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; OVERACTIVE BLADDER; PAIN; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; SKIN DISEASE; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE VOLUME; URODYNAMICS; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGED; BENZHYDRYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URODYNAMICS; YOUNG ADULT;

EID: 77950842803     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09037.x     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49 (Pubitemid 36151708)
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P International Continence Society. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006 25 : 293
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 336 (Pubitemid 44175300)
4. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 1315 (Pubitemid 44692945)
5. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 7 : 455 463 (Pubitemid 39038454)
6. MacDiarmid S, Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 2005 21 : 1413 1421 (Pubitemid 41368573)
7. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006 97 : 96 100
8. Nitti VW, Dmochowski R, Sand PK et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007 178 : 2488 2494 (Pubitemid 350052177)
9. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008 9 : 1787 1796
10. Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 2006 374 : 79 85 (Pubitemid 44657614)
11. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008 46 : 556 563
12. Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003 169 : 843 848 (Pubitemid 36188104)
13. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006 175 : 191 194 (Pubitemid 41797136)
14. Schafer W, Abrams P, Liao L et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002 21 : 261 274 (Pubitemid 34411846)
15. Pocock SJ. Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 1982 38 : 153 162
16. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 2003 92 : 415 417 (Pubitemid 37100520)
17. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009 103 : 931 937
18. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007 100 : 987 1006 (Pubitemid 47537675)
19. Groenendijk PM, Lycklamaa Nyeholt AA, Heesakkers JP et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008 101 : 325 329
20. Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol 2003 169 : 529 533 (Pubitemid 36132978)
21. Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006 176 : 367 373 (Pubitemid 43833174)
22. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003 62 (Suppl. 2 3 10
23. Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep 2008 9 : 459 464
24. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006 25 : 156 161
25. Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007 52 : 842 847 (Pubitemid 47126153)
26. Boy S, Schurch B, Mehnert U, Mehring G, Karsenty G, Reitz A. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 2007 100 : 574 578 (Pubitemid 47205445)
27. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human bladder and in urinary urgency. BJU Int 2005 95 : 1002 1005
28. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002 60 (Suppl. 1 13 20 (Pubitemid 36009214)
29. Salvatore S, Serati M, Digesu GA et al. Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008 19 : 701 704 (Pubitemid 351516948)